Clinical meaning
Applying Beers Criteria in clinical practice requires understanding both the age-related pharmacological vulnerabilities it addresses and the systematic approach to safer prescribing. The start low, go slow principle reflects the narrowed therapeutic window in elderly patients: reduced receptor reserve means standard adult doses often produce exaggerated pharmacodynamic effects — antihypertensives cause symptomatic orthostasis (baroreceptor sensitivity declines with aging), opioids produce deeper respiratory depression (reduced chemoreceptor responsiveness), and benzodiazepines cause profound sedation (increased GABA receptor sensitivity). Deprescribing is not simply stopping a medication — it requires a structured approach: (1) identify the target drug by reviewing indication, benefit timeframe, and ongoing necessity; (2) assess withdrawal risk (benzodiazepines require 25% dose reduction every 2 weeks to prevent seizures; PPIs need gradual taper over 2-4 weeks to avoid rebound acid hypersecretion; beta-blockers must be tapered to prevent rebound tachycardia and angina); (3) implement the taper with clear timeline; and (4) monitor for both withdrawal symptoms and disease recurrence. The STOPP/START criteria complement Beers by also identifying prescribing omissions — medications that SHOULD be prescribed but are commonly withheld in elderly patients (e.g., calcium and vitamin D in osteoporosis, statin after MI, anticoagulation for atrial fibrillation). Time-to-benefit analysis is essential: statins for primary prevention require 2-5 years to show benefit, making them inappropriate for patients with life expectancy under 2 years, while medications like analgesics and antihypertensives provide immediate symptomatic benefit regardless of prognosis.